WAVE Life Sciences (WVE) Misses Q2 EPS by 22c, Revenues Miss
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
Wave Life Sciences Reports Fourth Quarter and Full Year 2019 Financial Results and Provides Business Update
March 2, 2020 6:45 AM ESTInnovative pipeline of stereopure oligonucleotides focused on CNS diseases
32 mg data from both PRECISION-HD clinical trials on track for 2H 2020
Two additional CNS programs SNP3 and C9orf72 on track to initiate clinical development in 2H 2020
Wave to host investor conference call and webcast at 8:00 a.m. ET today
CAMBRIDGE, Mass., March 02, 2020 (GLOBE NEWSWIRE) -- Wave Life Sciences Ltd. (Nasdaq: WVE), a clinical-stage genetic medicines company committed to delivering life-changing treatments for people battling devastating diseases, today... More
